http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
개별검색 DB통합검색이 안되는 DB는 DB아이콘을 클릭하여 이용하실 수 있습니다.
통계정보 및 조사
예술 / 패션
<해외전자자료 이용권한 안내>
- 이용 대상 : RISS의 모든 해외전자자료는 교수, 강사, 대학(원)생, 연구원, 대학직원에 한하여(로그인 필수) 이용 가능
- 구독대학 소속 이용자: RISS 해외전자자료 통합검색 및 등록된 대학IP 대역 내에서 24시간 무료 이용
- 미구독대학 소속 이용자: RISS 해외전자자료 통합검색을 통한 오후 4시~익일 오전 9시 무료 이용
※ 단, EBSCO ASC/BSC(오후 5시~익일 오전 9시 무료 이용)
N/A The authors investigated 1,335 cases of colorectal carcinoma which were diagnosed with resected colon and rectum or fiberoptic biopsies from 1971 to 1990 in Pusan area. We analysed them statistically in epidemiological view point and obtained the following results. The time trends indicated that difference in the annual fluctuation of age-adjusted incidence rate of colorectal carcinoma durng last 20 years was statistically significant. In the sex ratio, the male incidence was higher than female ratio in the first term, but the incidences of both sex were similar in later term. The increase rate of the incidence of right colon carcinoma was similar to that of left colon carcinoma. The patient age at diagnosis ranged from 16 to 87 years. The mean was 47.8 (48.4 in male and 51.0 in female) iin first term and 53.0 (52.5 in male and 53.5 in female) in later term. The incidences of colorectal carcinoma in middle aged and old aged patients were increased with the time trend compared with that of young aged. The incidence rates of Dukes A and B in the first term were 4.1% and 17.3%, but those in the later term 4.6% and 35.8%, respectively. The increased rate of incidences of Dukes A and B stages were predominant in the left colon. From the above result, authors concluded that the epidemiological pattern of colorectal carcinoma among Korean in Pusan area showed a transition moving from ENDEMIC pattern to EPIDEMIC pattern of Haenszels epiderniological model for the colorectal carcinoma.
N/A To evaluate and compare therapeutic efficacy of adenine arabinoside (Ara-A) and alpha interferon (alpha-INF), 59 patients with biopsy proven chronic active hepatitis B were randomized to receive Ara-A (15 mg/kg/day for 10 days) or alpha-INF (total dose: 108 million units) and followed up 6 months after completion of therapy.All patients were HBeAg positive. Clinical effects of Ara-A and alpha-INF on seroconversion of HBeAg and levels of serum alanine aminotransferase (ALT) were closely matched and compared with those of untreated control group (30 cases). Seroconversion of HBeAg in alpha-INF treated group (30 cases) was observed in 11 cases (36.7%), showing higher seroconversion rate as compared to Ara-A treated (6/29 cases, 20.7%) and to control patients (0/30 cases, 0%). There were no effects of Ara-A on ALT levels in the treated patients as compared with the untreated control patients. However, ALT levels in the interferon treated patients were remarkably (p<0.005, ALT levels at 6 months after treatment: 83.37±98.83 IU/L) reduced as compared with the level of pretreatment level (256.74 ± 175,83 IU/L). The present study, thus, indicates that Ara-A is not recommended as a first choice of therapy in the treatement for the patients with HBeAg positive CAH, but interferon may be recommended for those patients and further study will be necessary with prolonged follow up.